Latest filing published 03 Jan 2024 for Coherus BioSciences, Inc., €55k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of McDavid Stilwell in Coherus Oncology, Inc. Between 28 April 2021 and 31 December 2023, the trades on record add up to 9 filings.
Market trades split into 1 purchase (€41k) and 1 sale (€51k). Sales outweigh purchases by €10k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 7 share grants.
On 3 January 2024 came the latest disclosure, a share grant for €55k in Coherus Oncology, Inc. The latest purchase dates back some time: it was published 1,962 days ago, on 10 June 2021. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations